Glypican 3 as target therapy to prevent cell migration and proliferation in rhabdomyosarcoma
Abstract Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma of mesenchymal origin with two main variants, the embryonal, less aggressive, and the alveolar RMS, more metastatic. The role of the extracellular matrix (ECM) in the growth and migration of RMS, as in other cancers, is becoming incr...
Saved in:
| Main Authors: | Maira Bacchiega, Stefania D’Agostino, Antonella Grigoletto, Elena Poli, Paolo Bonvini, Gianni Bisogno, Gianfranco Pasut, Michela Pozzobon |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-03466-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Normal Glypican-3 Serum Levels Do Not Eliminate the Risk of Hepatocellular Carcinoma
by: Agnieszka Lembas, et al.
Published: (2024-09-01) -
Pleomorphic rhabdomyosarcoma in adults: a case report
by: Zahra Aminparast, et al.
Published: (2025-04-01) -
Extracellular glypican‐1 affects tumor progression and prognosis in esophageal cancer
by: Rie Shibata, et al.
Published: (2024-09-01) -
Unraveling Glypican-3: From Structural to Pathophysiological Roles and Mechanisms—An Integrative Perspective
by: Qianling Piao, et al.
Published: (2025-05-01) -
Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights
by: Luca Filippi, et al.
Published: (2025-06-01)